The UK and US have reached a landmark bilateral deal that will guarantee no duties on UK drug shipments being sold in the American market.
Key Provisions of the Accord
As part of the deal, the UK has pledged to increase funding on medicines through the National Health Service (NHS). This commitment guarantees that duties on these crucial goods will be held at nothing for a duration of the next three years.
This development comes after recent threats to hike import taxes on branded drug imports, with figures mentioned up to one hundred percent.
"This agreement between the United Kingdom reinforces the worldwide climate for innovative medicines and establishes much-needed balance to transatlantic medicine commerce," a release noted.
Economic Importance
Pharmaceuticals represent one of the UK's largest goods shipped to the US, which is easily the biggest market for large UK drugmakers.
Trade data show that in the 12 months leading up to last September, the UK sold medicines worth billions to the US. This figure accounted for nearly one-fifth of total UK exports in that timeframe.
"This deal safeguards employment, increases investment and paves the way for the UK to establish itself as a global hub for medical research," a minister remarked.
Key NHS Changes
The deal involves several notable pledges from the British government:
- Higher Cost Ceiling: The UK will increase the price threshold at which it judges new therapies to be too expensive by a quarter.
- Higher Drug Budget: There is a target to raise overall health service expenditure on treatments from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Rebate Cap: The percentage drug companies must refund to the NHS to stay within budget will be limited at fifteen percent. In the past, refunds topped twenty percent.
Industry Background
This agreement follows a protracted dispute between the drug companies and the British authorities over spending levels and NHS adoption.
This friction were heightened by assertions that US patients were charged significantly more for the equivalent treatments than people in the UK and Europe.
In recent months, several large drug company projects in the UK have been paused or abandoned, while multi-billion-dollar funding commitments have been announced toward American operations.
A senior figure stated that the NHS needed to increase expenditure on drugs, noting that its expenditure on drugs had declined as a proportion of its resources over the last ten years.
